KFAS
CLDX icon

Keating Financial Advisory Services’s Celldex Therapeutics CLDX Stock Holding History

Keating Financial Advisory Services’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17K Hold
456
– – ﹤0.01% 1047
2026
Q1 		$14.5K Buy
+456
New +$12.4K ﹤0.01% 1011

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's CLDX Position: Q2 2026 in Review

Keating Financial Advisory Services held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 456 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1047.

Keating Financial Advisory Services first reported a position in CLDX in Q1 2026 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Keating Financial Advisory Services held 456 shares of Celldex Therapeutics worth $17K as of Q2 2026.
  • Keating Financial Advisory Services left its Celldex Therapeutics share count unchanged in Q2 2026.
  • Celldex Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1047 holding.
  • Keating Financial Advisory Services first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.